SRLast month, the private company StimRelieve, LLC, received approval from the United States Food & Drug Administration (FDA) to conduct a clinical trial of a stimulation device to treat chronic migraine. Called the StimRelieve Halo Migraine System, it is implanted under the skin and uses wireless neurostimulators to treat chronic migraine—migraine 15 or more days per month—that has not responded to other treatment.

OptiNoseA new device showing promise in migraine treatment is growing closer to potential approval by the United States Food & Drug Administration (FDA). The Pennsylvania-based company, OptiNose, recently announced that a pivotal phase III study evaluating the efficacy and safety of  the device, called AVP-825, will be published in the January 2015 issue of Headache, The Journal of Head and Face Pain. The study is currently available on the journal’s website through its early access feature.

Medications to prevent migraine have been slow in coming, but a treatment approach currently being studied suggests that a new type of drug may benefit countless migraineurs. This new method employs agents that block a protein called calcitonin gene-related peptide (CGRP), which plays a crucial role in migraine. The new drugs, anti-CGRP antibodies, bind to the protein and stop it from attaching to nerve receptors, preventing migraine in the process.

The U.S. Food and Drug Administration recently cleared the handheld device, SpringTMS, for the treatment of acute migraine with aura. SpringTMS, available by prescription, creates mild electrical currents that can depolarize neurons in the brain. Experts believe this action interrupts the abnormal hyperactivity associated with migraine. When treating themselves, patients simply hold the device at the back of their head and press a button. 

The first medical device to prevent migraines can now be marketed accordingly, due to U.S. Food and Drug Administration (FDA) approval last month. Called Cefaly, the device is placed like a crown on the head and delivers an electric current to stimulate branches of the trigeminal nerve, which has been associated with migraine headaches.

The U.S. Food and Drug Administration (FDA) recently approved Topamax (topiramate) for prevention of migraine headaches in adolescents ages 12 to 17. Topiramate is the first drug to earn FDA approval for migraine prevention in this age group. Although it was prescribed for young migraineurs before the approval, this step is expected to provide benefits to physicians and patients.

Q. I am suffering with new daily persistent headache. My headache began Jan. 21, 2012, and I have had it every day since. From what I have read, my situation is like others who have this condition. Medications do not seem to work, so I have continued to try new ones via a neurologist who specializes in headaches.  All tests are clear–MRI, MRA, MRV, CT scans, blood work and spinal tap. I have occasionally tried alternative methods–Botox, occipital nerve block, chiropractic care, naturopathy, Chinese herbalism, massage, yoga, Thai yoga therapy, none of which helped with the headache either. I have read that this can last from months to decades.  Is there any current information on the most successful approaches to make the headache go away?

Last month the U.S. Food and Drug Administration (FDA) rejected Levadex ®, an inhaled form of the migraine medication, dihydroergotamine (DHE). This is the second time the agency has failed to approve the medication. DHE has been used in migraine treatment for many years, but it is most effective when given intravenously or via intramuscular injection, requiring a hospital or clinic visit. A DHE nasal spray is also available but is slow to take effect. The inhaled form of the medication is meant to work quickly and can be used at home.